Navigation Links
Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
Date:10/24/2007

this study had enrolled 26 patients with a variety of advanced solid tumors. 11 of 21 patients assessable for tumor response receiving doses of XL647 ranging from 75 to 300 mg achieved stable disease for at least three months. The XL647 exposure with daily dosing at the maximum tolerated dose (MTD) (300 mg) in this study was approximately twofold higher over a 28-day cycle compared to the exposure observed previously at the MTD (350 mg) for the intermittent dosing regimen. XL647 was generally well tolerated and related Grade 3 adverse events were infrequent. No Grade 3 or greater skin rash was reported in this study. Pharmacodynamic analyses were conducted in plasma samples and eyebrow hair follicles. Biomarker changes consistent with EGFR inhibition were observed in eyebrow hair follicles following XL647 treatment.

"The phase 2 data continue to show encouraging anti-tumor activity for XL647 given on an intermittent schedule in previously untreated clinically selected NSCLC patients. Additionally, phase 1 data suggest that XL647 dosed daily at 300 mg is well tolerated and provides approximately twofold higher drug exposure over a 28-day cycle compared to intermittent dosing," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "We are pleased to continue to see evidence of good tolerability and no Grade 3 rash with XL647, and believe that a daily dosing strategy may have the potential to further enhance the anti-tumor activity in NSCLC."

The most common treatment-related adverse events (AEs) were Grade 1 and 2 diarrhea and dysgeusia, fatigue, rash, and clinically asymptomatic QTc prolongation. In phase 1, a total of ten serious AEs were reported in six patients; of these events, two were considered possibly or probably related to XL647. These two drug-related events of Grade 3 pneumonitis and Grade 4 myocardial infarction occurred in the same patient. The cohort was expanded, and no further dose-limiting toxicities (DLTs) w
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... MENLO PARK, Calif. , Sept. 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... the company has submitted its preliminary response to the ... two petitions for inter partes review (IPR), filed ... validity of certain claims in U.S. Patent No. 8,359,102 ...
(Date:9/1/2015)... and BRUSSELS , ... ) and UCB (Euronext Brussels: UCB) today announced ... effect of RomosozUmab Compared with Teriparatide in postmenopaUsal ... pReviously treated with bisphosphonatE therapy). The study (NCT01796301) ... difference in favor of romosozumab in the percent ...
(Date:9/1/2015)... N.J. , Sept. 1, 2015 Konica ... CS-7s Computed Radiography (CR) system, designed to deliver enterprise ... By utilizing the same Control Station as the Konica ... assured with an upgrade path from CR to DR. ... imaging to help improve workflow with unparalleled reliability and ...
Breaking Medicine Technology:Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to be the ... of getting ovarian cancer in her lifetime is approximately 1 in 75. This year ... cancer, and 14,000 will die. , There is no test to detect ovarian ...
(Date:9/2/2015)... ... September 02, 2015 , ... Lakeview Health, a ... to International Overdose Awareness Day. The goal is to provide people information regarding ... so that they may get help. , Lakeview Health will be ...
(Date:9/2/2015)... ... September 02, 2015 , ... Available ... marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream , an evolution ... biotechnological anti-aging power with a lipid-replenishing marine oil for intense nourishing and moisturizing. ...
(Date:9/2/2015)... ... 2015 , ... Please join the world renowned Brain Aneurysm ... established by the Foundation in 2007 with the help of Massachusetts State Representative ... remains our top priority,” commented Christine Buckley, Executive Director of the Brain Aneurysm ...
(Date:9/2/2015)... ... September 02, 2015 , ... Canopy Partners, a ... to the Inc. 5000 List, an independent ranking of the fastest- growing ... years, and this achievement puts Canopy in rarefied company. Over the years, this ...
Breaking Medicine News(10 mins):Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2
... can do well with stress busters. According to a world ... Taiwan on top of the list. China, the Philippines,// Botswana, ... their ranks on the “Stressed Out” Statistics. ,Businessmen ... 7000 businessmen from 30 countries were observed , amongst them ...
... Yoga guru Ramdev signed agreements with the Jharkhand government to ... of herbal plants.// ,The memorandums of understanding were signed ... ,Announcing government aid of Rs.10 million for the ... Jharkhand as a herbal state that can benefit the common ...
... University researcher Chensheng "Alex" Lu, PhD, 'Organic diets lower ... U.S. agricultural production.'// ,The fact is ... items. The result was that concentration of pesticides was ... by Dr. Lu, "The use of organophosphorus pesticides in ...
... to you readers but if new research is to be believed ... ,This revelation comes from American scientists who found that the ... by way of an increase the number of nerve connections in ... ,The Yale University is credited with the study and it ...
... Epidemiology Unit Director Dr Nihal Abeysinghe said that the country ... This is due to the result of the confirmation of ... are requesting the public to avoid importing poultry products from ... not contained by the Indian authorities then there is an ...
... of anabolic steroids, more specifically anabolic androgen steroid (AAS) ... sebaceous glands. Sebaceous glands present in the skin // ... of the body surface. ,Anabolic steroids are ... to treat unwanted weight loss in patients with HIV. ...
Cached Medicine News:Health News:Bird flu affects the export of poultry products to Sri Lanka and Nepal 2
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
... pipette is ideal for repeated ... Fixed volume FInnpipettes offer the ... other Finnpipette Digital pipettes: ... (1-40ul), Soft-touch tip ejection, Safety ...
Medicine Products: